174 related articles for article (PubMed ID: 27396387)
1. Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters.
Zhao C; Han SY; Li PP
Curr Drug Deliv; 2017; 14(2):282-288. PubMed ID: 27396387
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of tyrosine kinase inhibitors.
van Erp NP; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding JF; Zhong DF
Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
[TBL] [Abstract][Full Text] [Related]
5. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Li J; Zhao M; He P; Hidalgo M; Baker SD
Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
8. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
[TBL] [Abstract][Full Text] [Related]
9. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Kawamura K; Yamasaki T; Yui J; Hatori A; Konno F; Kumata K; Irie T; Fukumura T; Suzuki K; Kanno I; Zhang MR
Nucl Med Biol; 2009 Apr; 36(3):239-46. PubMed ID: 19324269
[TBL] [Abstract][Full Text] [Related]
11. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
Wang C; Liu KX
Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.
Bergman E; Forsell P; Persson EM; Knutson L; Dickinson P; Smith R; Swaisland H; Farmer MR; Cantarini MV; Lennernäs H
Int J Pharm; 2007 Aug; 341(1-2):134-42. PubMed ID: 17482782
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib.
Rahman AF; Korashy HM; Kassem MG
Profiles Drug Subst Excip Relat Methodol; 2014; 39():239-64. PubMed ID: 24794908
[TBL] [Abstract][Full Text] [Related]
14. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
[TBL] [Abstract][Full Text] [Related]
15. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Li J; Karlsson MO; Brahmer J; Spitz A; Zhao M; Hidalgo M; Baker SD
J Natl Cancer Inst; 2006 Dec; 98(23):1714-23. PubMed ID: 17148773
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Fang P; Zheng X; He J; Ge H; Tang P; Cai J; Hu G
Drug Des Devel Ther; 2017; 11():1283-1290. PubMed ID: 28461741
[TBL] [Abstract][Full Text] [Related]
17. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.
Joyce H; McCann A; Clynes M; Larkin A
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):795-809. PubMed ID: 25836015
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism.
Liu X; Lu Y; Guan X; Dong B; Chavan H; Wang J; Zhang Y; Krishnamurthy P; Li F
Biochem Pharmacol; 2015 Sep; 97(1):111-21. PubMed ID: 26212543
[TBL] [Abstract][Full Text] [Related]
20. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
Bi Y; Deng J; Murry DJ; An G
AAPS J; 2016 Jan; 18(1):228-38. PubMed ID: 26559435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
